EGFR also contributes to the development and progression of breast cancers [26, 27] and is overexpressed in approximately 50% of the Triple-Negative Breast Cancers (TNBCs) that lack Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 [28]. Here, ERBB2 is linked to triple-negative breast carcinoma.